| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Doyle Anthony serves as a Chief Financial Officer at BCRX. Across recent SEC filings that breaks down to 3 buys and 1 sell. Those positions are worth an estimated $2.8M at current prices.
Historically, Doyle Anthony's trades have earned a strong insider score of 70/100 across 3 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +42.2%.
The biggest single holding is BCRX (~$2.8M) as Chief Financial Officer. Net of sales, the recent Form 4 record there shows accumulation of 119,858 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2024 | BCRX Biocryst Pharmaceuticals Inc | Chief Financial Officer | Buy | 36,300 | $5.57 | $202,191.00 | +15.8% | +44.2% | +83.8% | |
| Dec 15, 2022 | BCRX Biocryst Pharmaceuticals Inc | Chief Financial Officer | Sell | 5,700 | $10.90 | $62,130.00 | -3.4% | -22.6% | -42.7% | |
| Nov 23, 2021 | BCRX Biocryst Pharmaceuticals Inc | Chief Financial Officer | Buy | 35,258 | $12.48 | $440,019.84 | +60.3% | +43.5% | +0.2% | |
| Aug 11, 2020 | BCRX Biocryst Pharmaceuticals Inc | Chief Financial Officer | Buy | 54,000 | $4.08 | $220,320.00 | New | - | - |